Search clinical trials for: IOA-289

Total 3967 results

Nanjing Medical University
Beijing Anzhen Hospital; Second Affiliated Hospital of Nanchang University

Recruiting

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Thymosin α1) V

Acute Aortic Syndrome | Aortic Dissectio

China
iOnctura

Completed

A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers

Healthy

Italy
Jeil Pharmaceutical Co., Ltd.

Unknown

Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke

Acute Ischemic Stroke

Korea, Republic of
Jeil Pharmaceutical Co., Ltd.

Completed

The Evaluation of Safety, Tolerability and Pharmacokinetics of Stroke Targeting Drug in Healthy Volunteers (JPI-289)

Stroke

Korea, Republic of
Jeil Pharmaceutical Co., Ltd.

Completed

The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers

Stroke

Korea, Republic of
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
iOnctura

Recruiting

A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

Italy, United Kingdom
Bristol-Myers Squibb
National Cancer Institute (NCI)

Withdrawn

Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

Melanoma (Skin)
Addpharma Inc.

Completed

A Study to Evaluate the Efficacy and Safety of AD-209

Hypertension, Essential

Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Melanoma (Skin)

United States
Mount Sinai Hospital, Canada

Not yet recruiting

Mechanical Bowel Prep Randomized Study

Colorectal Surgery
Terrence J Bradley, MD
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...

Recruiting

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

Polycythemia Vera | Essential Thrombocythemia

United States
Neuralstem Inc.

Unknown

A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Amgen

Completed

A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.

Asthma

United States
OSE Immunotherapeutics

Recruiting

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Lymphoma | Solid Advanced Tumor

France, Belgium
Becton, Dickinson and Company

Completed

Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Boehringer Ingelheim

Completed

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

Healthy
Hutchison Medipharma Limited

Completed

A Study of HMPL-689 in Healthy Volunteers

Healthy Volunteers

Australia
Neuralstem Inc.

Unknown

Study of NSI-189 for Major Depressive Disorder

Major Depressive Disorder

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Cognitive Deficits in Schizophrenia

United States
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Cystic Fibrosis
Takeda

Recruiting

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Biomea Fusion Inc.

Recruiting

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditions

United States, Korea, Republic of
Takeda
Takeda Development Center Americas, Inc.

Recruiting

First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer

Unresectable Locally Advanced or Metastatic Cancer

Spain, United States, Australia, Canada
Foghorn Therapeutics Inc.

Terminated

FHD-286 in Subjects With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

United States, Netherlands, France
BeiGene

Completed

The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor

Solid Tumors

China
AbbVie (prior sponsor, Abbott)

Completed

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Addpharma Inc.

Recruiting

Phase III Study to Evaluate the Efficacy and Safety of AD-209

Hypertension,Essential

Korea, Republic of
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Cystic Fibrosis
Rapport Therapeutics Inc.

Not yet recruiting

Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

Focal Onset Seizures
Afasci Inc

Recruiting

Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers

Pain, Neuropathic | Pain, Inflammatory

United States
Teva takeda

Completed

A Study of TAK-279 in Adults With or Without Kidney Problems

Renal Impairment | Healthy Volunteers

United States
Giselle Sholler
Cortice Biosciences, Inc.

Terminated

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Medulloblastoma | Neuroblastoma

United States
Hutchison Medipharma Limited

Completed

A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed

Lymphomas

China
BeiGene

Completed

Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

Solid Tumors

Australia, New Zealand
Otsuka Pharmaceutical Co., Ltd.

Completed

Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis

Pain Due to Osteoporosis

Japan
Abbott

Terminated

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Biomea Fusion Inc.

Recruiting

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus (BF-MNN-112)

Type 1 Diabetes Mellitus

United States, Canada
Hutchmed

Active, not recruiting

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

Lymphoma

Spain, United States, France, Italy, Finland, Poland
AbbVie (prior sponsor, Abbott)

Completed

A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Tasly Pharmaceuticals, Inc.

Completed

A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes

Stable Angina

United States
Abbott

Terminated

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Alzheimer's Disease

United States
Abbott

Terminated

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Alzheimer's Disease

United States
Boehringer Ingelheim

Completed

Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

Healthy
Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.
PATH; World Health Organization; Xinhua Hospital, Shanghai Jiao Tong University... and other collaborators

Completed

A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate

Prophylaxis Against Plasmodium Falciparum Malaria

China
Millennium Pharmaceuticals, Inc.

Completed

A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer

Cancer

United States
Takeda

Recruiting

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, France, Hungary, Korea, Republic of, Belgium, Japan, Germany, Canada, Italy, Poland, Czechia, Denmark, Greece, Norway, Romania, Slovakia, United Kingdom
CStone Pharmaceuticals
Blueprint Medicines Corporation

Completed

A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors

China
Boehringer Ingelheim

Completed

Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers

Hepatic Insufficiency

Search clinical trials for: IOA-289

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations